Expanded Surveillance for New Vaccine Preventable Diseases

0
65

Opportunity ID: 328354
Opportunity Number: RFA-IP-21-002
Opportunity Title: Expanded Surveillance for New Vaccine Preventable Diseases
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Category Explanation:
CFDA Number(s): 93.083
Eligible Applicants: State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Additional Information on Eligibility:
Agency Code: HHS-CDC-HHSCDCERA
Agency Name: Department of Health and Human Services
Centers for Disease Control and Prevention – ERA
Posted Date: Jul 29, 2020
Last Updated Date: Jul 29, 2020
Estimated Synopsis Post Date: Dec 01, 2020
Fiscal Year: 2021
Award Ceiling: $1,000,000
Award Floor: $150,000
Estimated Total Program Funding: $35,000,000
Expected Number of Awards: 7
Description: The purpose of this notice of funding opportunity is to solicit applications for a research cooperative agreement that will fund a network of pediatric medical institutions to conduct prospective, active surveillance for acute gastroenteritis (AGE) and acute respiratory illnesses (ARI) in inpatient and emergency department clinical settings, including healthy controls. The Core Component award will fund activities for a US pediatric vaccine-preventable, or possibly vaccine-preventable, disease surveillance system for a variety of AGE and ARI pathogens. The surveillance system will enable the assessment of pediatric infectious disease burden, understanding of the natural history of pediatric infectious disease, disease transmission dynamics, vaccine effectiveness evaluations and vaccine impact for vaccine-preventable pathogens or those having potential new vaccines in development.
Version: 1





Visit the Official Webpage For More Details on Expanded Surveillance for New Vaccine Preventable Diseases